The meeting will feature a presentation by
Bellerophon's management team will also provide an overview of the Company’s ongoing clinical development program with its proprietary INOpulse® therapy, which is designed to deliver pharmaceutical-grade nitric oxide in a targeted fashion to the well-ventilated sections of the patient's lung. Bellerophon will focus on its ongoing Phase 2/3 clinical study to progress INOpulse for the treatment of PH-ILD. The Company previously reported positive results from Cohort 1 in which subjects on active treatment demonstrated a clinically and statistically significant improvement of 34% in moderate to vigorous physical activity (MVPA) as compared to subjects on placebo, as well as improvements in overall activity, oxygen saturation and additional functional measures. Bellerophon has agreement with the
Dr. Nathan is Medical Director of the Advanced Lung Disease and Lung Transplant Program at
This event is intended for institutional investors, sell-side analysts, investment bankers, and business development professionals only. Please RSVP in advance if you plan to attend, as space is limited. Members of the media and the public are invited to participate via the live webcast.
Any statements in this press release about Bellerophon’s future expectations, plans and prospects, including statements about the clinical development of its product candidates, regulatory actions with respect to the Company’s clinical trials and expectations regarding the sufficiency of the Company’s cash balance to fund clinical trials, operating expenses and capital expenditures, and other statements containing the words “anticipate,” “believe,” “continue,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would,” and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the uncertainties inherent in the initiation of future clinical trials, availability and timing of data from ongoing and future clinical trials and the results of such trials, whether preliminary or interim results from a clinical trial will be predictive of the final results of that trial or whether results of early clinical trials will be indicative of the results of later clinical trials, expectations for regulatory approvals, the FDA’s substantial discretion in the approval process, availability of funding sufficient for our foreseeable and unforeseeable operating expenses and capital expenditure requirements and other factors discussed in the “Risk Factors” section of the Company’s most recent Annual Report on Form 10-K and in subsequent filings with the
|At Bellerophon:||At LifeSci Advisors:|
|Fabian Tenenbaum, Chief Executive Officer||Brian Ritchie|
|(908) 574-4767||(212) 915-2578|
Source: Bellerophon Therapeutics, Inc.